Aquestive Therapeutics, Inc. develops and commercializes innovative pharmaceutical products using its proprietary PharmFilm technology, focusing on central nervous system disorders and other therapeutic areas. On June 25, 2026, with the market open, AQST shares traded at $4.2750, down 14.33% from the prior session's close of $4.9900. The decline reflects selling pressure without an immediate identifiable news trigger, as the stock pulled back from recent gains.
Trading volume exceeded the average, indicating heightened investor activity. The selloff aligned with softer sentiment across select small-cap healthcare peers, though major indices showed mixed performance. Technical levels near recent support were tested as the price moved lower intraday.
The drop took place against a backdrop of variable performance in the specialty pharmaceuticals sector. While AQST had benefited earlier from positive clinical and financing updates, today's action appeared driven more by profit-taking and general risk-off flows in smaller biotech and pharma names rather than any fundamental shift in the company's outlook.
Tickeron’s Trending AI Robots page highlights the strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with only the top performers featured in this curated section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade. Investors seeking automated trading insights can explore the platform for additional tools and strategies.
Investors will watch for regulatory progress on the Anaphylm sublingual film NDA resubmission targeted for the third quarter. The company is also expected to report second-quarter results around August 11. Key risks include clinical development timelines, regulatory decisions, and ongoing cash burn typical of development-stage biopharma firms. Market participants will continue to assess sector sentiment and any new corporate announcements.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
AQST moved above its 50-day moving average on August 10, 2026 date and that indicates a change from a downward trend to an upward trend. In of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on AQST as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AQST just turned positive on August 06, 2026. Looking at past instances where AQST's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for AQST crossed bullishly above the 50-day moving average on August 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AQST advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
AQST broke above its upper Bollinger Band on August 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AQST entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (47.296). P/E Ratio (0.000) is within average values for comparable stocks, (94.190). AQST's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.238). AQST has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (11.299) is also within normal values, averaging (177.127).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AQST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer thin film pharmaceutical and over the counter drug products
Industry PharmaceuticalsGeneric